WallStSmart

Merck & Company Inc (MRK)vsShattuck Labs Inc (STTK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6656800% more annual revenue ($66.57B vs $1.00M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

STTK

Avoid

23

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -1.66
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for STTK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

STTK1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

STTK4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$682.47M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : STTK

The strongest argument for STTK centers on Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : STTK

The primary concerns for STTK are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

STTK carries more volatility with a beta of 1.10 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (36/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Shattuck Labs Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.

Want to dig deeper into these stocks?